论文部分内容阅读
目的分析系统性红斑狼疮患者骨髓巨核细胞数量与血小板减少的临床联系,探讨系统性红斑狼疮患者的发病机制。方法将河北省沧州市中心医院2010年1月至2012年12月收治的80例系统性红斑狼疮患者,按照骨髓巨核细胞数量分为巨核细胞增生活跃组与巨核细胞增生低下组,观察两组患者的血小板数量、尿蛋白和免疫球蛋白以及自身抗体与补体、疾病活动度等情况。结果巨核细胞增生活跃组共有50例,比例为62.5%;巨核细胞增生低下组共有30例,比例为37.5%,有明显的差异(P<0.05);巨核细胞增生活跃组与巨核细胞增生低下组的补体C3数据比较具有明显的差异(P<0.05);两组年龄、病程、尿蛋白、血小板计数、免疫球蛋白升高率、dsDNA、抗ENA、抗核抗体、抗膜相关DNA、抗心磷脂体、SLEDAI评分及血小板减少率比较无明显的差异(P>0.05)。结论血小板减少的系统性红斑狼疮患者骨髓巨核细胞增生活跃强,并且骨髓巨核细胞数量对血小板减少系统性红斑狼疮患者的疾病程度无任何的影响。
Objective To analyze the clinical relationship between the number of bone marrow megakaryocytes and thrombocytopenia in patients with systemic lupus erythematosus and to explore the pathogenesis of systemic lupus erythematosus. Methods Eighty patients with systemic lupus erythematosus who were admitted from January 2010 to December 2012 in Cangzhou Central Hospital of Hebei Province were divided into megakaryocyte hyperplasia active group and megakaryocyte hyperplasia active group according to the number of bone marrow megakaryocytes. Platelet count, urinary protein and immunoglobulin and autoantibodies and complement, disease activity and so on. Results In the megakaryocyte hyperplasia active group, there were 50 cases, accounting for 62.5%; in the megakaryocyte hyperplasia group, there were 30 cases (37.5%) with significant difference (P <0.05); the megakaryocyte hyperplasia active group and the megakaryocyte hyperplasia group (P <0.05). There was no significant difference in age, course of disease, urinary protein, platelet count, immunoglobulin increased rate, dsDNA, anti-ENA, antinuclear antibody, anti-membrane related DNA, There was no significant difference in phospholipid, SLEDAI score and thrombocytopenia (P> 0.05). Conclusion Thrombocytopenic patients with systemic lupus erythematosus bone marrow megakaryocyte hyperplasia, and the number of bone marrow megakaryocytes in patients with thrombocytopenic systemic lupus erythematosus did not affect the extent of the disease.